- Home
- AVXL vs KALV Comparison
AVXL vs KALV Comparison
Compare AVXL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- KALV
- Stock Information
- Founded
- AVXL 2004
- KALV N/A
- Country
- AVXL United States
- KALV United States
- Employees
- AVXL N/A
- KALV N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- KALV Health Care
- Exchange
- AVXL Nasdaq
- KALV Nasdaq
- Market Cap
- AVXL 794.0M
- KALV 642.3M
- IPO Year
- AVXL N/A
- KALV N/A
- Fundamental
- Price
- AVXL $10.84
- KALV $11.83
- Analyst Decision
- AVXL Strong Buy
- KALV Strong Buy
- Analyst Count
- AVXL 2
- KALV 8
- Target Price
- AVXL $44.00
- KALV $24.83
- AVG Volume (30 Days)
- AVXL 890.2K
- KALV 1.1M
- Earning Date
- AVXL 08-05-2025
- KALV 07-10-2025
- Dividend Yield
- AVXL N/A
- KALV N/A
- EPS Growth
- AVXL N/A
- KALV N/A
- EPS
- AVXL N/A
- KALV N/A
- Revenue
- AVXL N/A
- KALV N/A
- Revenue This Year
- AVXL N/A
- KALV N/A
- Revenue Next Year
- AVXL N/A
- KALV N/A
- P/E Ratio
- AVXL N/A
- KALV N/A
- Revenue Growth
- AVXL N/A
- KALV N/A
- 52 Week Low
- AVXL $4.00
- KALV $7.30
- 52 Week High
- AVXL $14.44
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- AVXL 75.85
- KALV 44.67
- Support Level
- AVXL $9.08
- KALV $11.10
- Resistance Level
- AVXL $9.78
- KALV $12.00
- Average True Range (ATR)
- AVXL 0.53
- KALV 0.85
- MACD
- AVXL 0.19
- KALV -0.10
- Stochastic Oscillator
- AVXL 95.03
- KALV 56.34
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.